Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.

Breast cancer research and treatment - 6 Jan 2026

Tahaney William M, Lanier Amanda, Qian Jing, Moyer Cassandra L, Nguyen Nghi, Ma Yanxia, Hill Jamal, Powell Reid T, Stephan Clifford C, Davies Peter J A, Mazumdar Abhijit, Brown Powel H

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of tumor protein 53 (TP53) mutation and with limited targeted therapies. Despite being clinically advantageous, direct targeting of mutant TP53 has been challenging. Therefore, we hypothesized that p53-mutant TNBC cells rely upon other potentially targetable survival pathways. METHODS: In vitro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Ferroptosis

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41493644
DOI: 10.1007/s10549-025-07865-6
PMCID: PMC12774971

Genes

TP53
GPX4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.PMID 41493644Read ↗

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast CancerSemantic proximity Read ↗

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivoSemantic proximity Read ↗

Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer ManagementSemantic proximity Read ↗

Gankyrin inhibits ferroptosis through the P53/SLC7A11/GPX4 axis in Triple-negative breast cancer cellsSemantic proximity Read ↗

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerSemantic proximity Read ↗

Inhibition of mitochondrial genome-encoded mitomiR-3 contributes to ZEB1 mediated GPX4 downregulation and pro-ferroptotic lipid metabolism to induce ferroptosis in breast cancer cellsSemantic proximity Read ↗

Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilienceSemantic proximity Read ↗

Halicin Reduces the Warburg Effect and Overcomes Drug Resistance by Activating the Pyruvate Kinase M2 Pathway for Triple-Negative Breast Cancer TreatmentSemantic proximity Read ↗

Taraxerol induces ferroptosis in breast cancer by targeting Nrf2 transcriptional activity to promote MIB2-mediated GPX4 ubiquitinationSemantic proximity Read ↗

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read ↗

BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1 -Deficient CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.